Moderna, Inc. Stock price

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
104.3 USD +0.39% Intraday chart for Moderna, Inc. -6.89% +4.84%
Sales 2024 * 4.22B Sales 2025 * 4.93B Capitalization 39.92B
Net income 2024 * -2.78B Net income 2025 * -1.95B EV / Sales 2024 * 8.34 x
Net cash position 2024 * 4.73B Net cash position 2025 * 3.38B EV / Sales 2025 * 7.41 x
P/E ratio 2024 *
-14.4 x
P/E ratio 2025 *
-20.6 x
Employees 5,600
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.18%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.01%
1 week-6.89%
Current month+13.03%
1 month+17.98%
3 months+22.06%
6 months+0.12%
Current year+4.84%
More quotes
1 week
100.94
Extreme 100.9399
112.65
1 month
85.53
Extreme 85.53
114.25
Current year
84.06
Extreme 84.06
115.97
1 year
62.55
Extreme 62.55
163.24
3 years
62.55
Extreme 62.55
497.49
5 years
11.54
Extreme 11.54
497.49
10 years
11.54
Extreme 11.54
497.49
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 11-02-28
Director of Finance/CFO 47 22-09-05
President 48 12-12-31
Members of the board TitleAgeSince
Director/Board Member 65 18-05-31
Director/Board Member 75 20-06-30
Director/Board Member 67 19-12-10
More insiders
Date Price Change Volume
24-03-18 104.3 +0.39% 4,034,481
24-03-15 103.8 +0.38% 5,464,806
24-03-14 103.5 -2.86% 4,635,880
24-03-13 106.5 -3.55% 5,122,006
24-03-12 110.4 -1.38% 4,180,437

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
104.3 USD
Average target price
133.8 USD
Spread / Average Target
+28.30%
Consensus
  1. Stock
  2. Equities
  3. Stock Moderna, Inc. - Nasdaq